ScholarLens Back to search
2010•Shandong yiyaoRequires access

Role of AFP-L3 in diagnosis and treatment of hepatocellular carcinoma

Han Youzhi

Open publisher page 0 citations

Abstract

Objective To explore the role of alpha-fetoprotein isoform-L3(AFP-L3) as a biomarker in diagnosis and treatment of hepatocellular carcinoma(HCC).Method AFP-L3 level and alpha-fetoprotein(AFP) level were measured in 112 serum samples by ELISA immunoassay kit.Results The positive rate of AFP-L3 in patients with HCC was 81.7%,which was significantly higher than that of the patients with benign liver tumors(10.5%) and the patients with liver cirrhosis(18.2%)(P0.05).The 1-year,2-year and 3-year survival rate after operation in AFP-L3 positive group were 77.3%,45.5%,22.7%,while they were 75.6%,53.7%,41.5% in negative group respectively.Conclusion AFP-L3 is a valuable biomarker in diagnosis and prediction of prognosis of HCC.

About this research paper

What this paper is about

Objective To explore the role of alpha-fetoprotein isoform-L3(AFP-L3) as a biomarker in diagnosis and treatment of hepatocellular carcinoma(HCC).Method AFP-L3 level and alpha-fetoprotein(AFP) level were measured in 112 serum samples by ELISA immunoassay kit.Results The positive rate of AFP-L3 in patients with HCC was 81.7%,which was significantly higher than that of the patients with benign liver tumors(10.5%) and the patients with liver cirrhosis(18.2%)(P0.05).The 1-year,2-year and 3-year survival rate after operation in AFP-L3 positive group were 77.3%,45.5%,22.7%,while they were 75.6%,53.7%,41.5% in negative group respectively.Conclusion AFP-L3 is a valuable biomarker in diagnosis and prediction of prognosis of HCC.

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Objective To explore the role of alpha-fetoprotein isoform-L3(AFP-L3) as a biomarker in diagnosis and treatment of hepatocellular carcinoma(HCC).Method AFP-L3 level and alpha-fetoprotein(AFP) level were measured in 112 serum samples by ELISA immunoassay kit.Results The positive rate of AFP-L3 in patients with HCC was 81.7%,which was significantly higher than that of the patients with benign liver tumors(10.5%) and the patients with liver cirrhosis(18.2%)(P0.05).The 1-year,2-year and 3-year survival rate after operation in AFP-L3 positive group were 77.3%,45.5%,22.7%,while they were 75.6%,53.7%,41.5% in negative group respectively.Conclusion AFP-L3 is a valuable biomarker in diagnosis and prediction of prognosis of HCC.

Key concepts: Hepatocellular carcinoma, Alpha-fetoprotein, Cirrhosis, Medicine, Gastroenterology, Internal medicine, Biomarker, Carcinoma

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Role of AFP-L3 in diagnosis and treatment of hepatocellular carcinoma — Research Paper | ScholarLens